Adjuvant chemotherapy for breast cancer

Langenbeck's Archives of Surgery

Volumn 387, Issue 3-4, 2002, Pages 109-116

  Green, Marjorie C ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Review; Therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG USE; FEMALE; HUMAN; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TOXICITY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; PACLITAXEL; PATIENT SELECTION; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036938587     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-002-0288-8     Document Type: Review

References (50)

1. Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528-534
2. Skipper HE (1986) On mathematical modeling of critical variables in cancer treatment (goals: Better understanding of the past and better planning in the future). Bull Math Biol 48:253-278
3. Skipper HE (1971) Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28:1479-1499
4. Skipper HE, Simpson-Herren L (1985) Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy. Important Adv Oncol 63-77
5. Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492
6. Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41:1170-1178
7. Rosen PP, Groshen S, Kinne DW, Norton L (1993) Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11:2090-2100
8. Fisher B, Fisher ER, Redmond C (1986) Ten-year results from the national surgical adjuvant breast and bowel project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard in the management of primary breast cancer. J Clin Oncol 4:929-941
9. Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528-534
10. Bonadonna G, Brusamolino E, Valagussa P, Bonadonna G, Veronesi U, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410
11. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant Cyclophosphamide, Methotrexate, and Flurouracil in Node-Positive Breast Cancer. N Engl J Med 332:901-906
12. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B-16. J Clin Oncol 8:1005-1018
13. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O'Sullivan J, Hess E, Martino S (1997) Tamoxifen (T) versus cyclophosphamide, Adriamycin and 5FU plus either concurrent or sequential T in postmenopausal, receptor (+), node (+) breast cancer: a Southwest Oncology Group phase III intergroup trial. Proc Am Soc Clin Oncol: abstract 450
14. Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Lew D, Martino S, Osborne C (2001) Overall survival after cyclophosphamide, Adriamycin 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: new findings from phase III southwest oncology group intergroup trial S8814 (INT-0100) Proc Am Soc Clin Oncol: abstract 94
15. Fisher B, Dingnam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG (1996) Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor negative tumors: eight-year results from national surgical adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, and fluorouracil. J Clin Oncol 14:1971-1973
16. Fisher B, Dingam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682
17. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930-942
18. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A (2001) Polychemotherapy for early breast cancer: an overview of the randomized clinical trials with quality-adjusted survival analysis. Lancet 358:277-286
19. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positivenode breast cancer patients with tamoxifen-non responsive tumors: Results of the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496
20. Coombes RC, Bliss JM, Wils J, Morvan F, Espie M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Perez-Lopez FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M (1996) Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14:35-45
21. Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathe G (1996) Adjuvant treatment of node positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145
22. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658
23. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K (1998) CMF versus CAF with and without Tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in lowrisk node negative patients: first results of intergroup trial INT 0102. Proc Am Soc Clin Oncol 17: abstract 1
24. Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK (2000) Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast cancer. Cancer 89:2521-2526
25. Piccart MJ, DiLeo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM (2001) Phase III trial comparing two dose levels of epirubicin compared with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer. J Clin Oncol 19:3103-3110
26. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942
27. Paradiso A, Schittulli F, Cellamare G, Mangia A, Marzullo F, Lorusso V, De Lena M (2001) Randomized clinical trial of adjuvant Fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 19:3929-3937
28. Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P, Nistico C, Di Filippo F, Vasselli S, Vici P, Botti C (2000) Role of P53 and BCL-2 in highrisk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol 126:722-729
29. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S (2001) Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? J Surg Res 99:161-168
30. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056
31. Allred DC, Clark GM, Tandon AK, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605
32. Muss HB, Thor AD, Berry DA, et al (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 331:1260-126
33. Yaamaauchi H, Steams V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356
34. Henderson IC, Berry D, Demetri G, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M (1998) Improved disease free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with nodepositive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101A, abstract 390
35. National Institutes of Health Consensus Development Panel (2000) National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989
36. Thomas E, Buzdar A, Theriault R, Singletary S, Booser D, Valero V, Ibrahim N, Smith T, Frye D, Manuel N, Kau S-W, McNeese M (2000) Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial. Proc Am Soc Clin Oncol 19: abstract 285
37. Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39:3861-3865
38. Goldhirsch A, Castiglione M, Gelber RD (1992) A single perioperative adjuvant chemotherapy course for nodenegative breast cancer: five year results of trial V. International Breast Cancer Study Group. J Natl Cancer Inst monographs vol 11, pp 89-96
39. Clahsen PC, van de Velde CJ, Goldhirsch A, Rossbach J, Sertoli MR, Bijnens L, Sylvester RJ (1997) Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. J Clin Oncol 15:252-235
40. Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T (1985) Short perioperative versus long-term adjuvant chemotherapy. Recent Results Cancer Res 98:91-98
41. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2:163-169
42. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184
43. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut bergonie bordeaux groupe sein (IBBGS). Ann Oncol 10:47-52
44. Jakesaz R (2001) Comparison of prevs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian breast and colorectal cancer study group (ABCSG) trial 7. Proc Am Soc Clin Oncol: abstract 125
45. Van der Hage JA, van de Velde CJH, Duchateau L, Julien JP, Tubiana-Hulin M (2000) Pre-operative chemotherapy in primary operable breast cancer; results of the EORTC trial 10902. Eur J Cancer 36 [Suppl 5]:S67
46. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 15:2479-2482
47. Fisher B, Bryant J, Wolmark N, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
48. Wolff AC, Davidson NE (2000) Primary systemic therapy in operable breast cancer. J Clin Oncol 18:1558-1569
49. Green MC, Hortobagyi GN (2002) Neoadjuvant chemotherapy for operable breast cancer. Oncology (in press)
50. Hortobagyi GN, Buzdar AU (1995) Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 45:199-226